Summary & Overview
HCPCS Level II J9020: Injection, asparaginase, 10,000 units
Headline: HCPCS Level II code J9020 covers asparaginase injections used in cancer chemotherapy
Lead: HCPCS Level II code J9020 denotes a 10,000-unit injection of asparaginase, a chemotherapeutic agent commonly used in the treatment of acute leukemias. The code identifies the drug product for billing and administrative workflows and is relevant across outpatient infusion centers and physician offices nationwide.
What the code represents and why it matters: J9020 specifies the administered drug and dose unit for asparaginase, enabling consistent reporting of chemotherapy drug delivery. Accurate coding supports clinical documentation, claim processing, and pharmacy inventory control, and informs payer coverage and prior authorization processes.
Key payers covered: The analysis references national commercial payers including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare.
What readers will learn: The publication provides clinical context for asparaginase use in chemotherapy, compares related HCPCS drug codes, and flags common billing considerations such as site-of-service implications and service-line documentation. It summarizes typical settings where J9020 is billed (outpatient infusion and office-based injections) and outlines associated clinical indications tied to acute leukemia treatment.
Limitations: Data not available in the input for specific utilization rates, reimbursement benchmarks, and payer policy details. These items are noted where applicable.
Billing Code Overview
HCPCS Level II code J9020 represents Injection, asparaginase, not otherwise specified, 10,000 units. This code is used to report administration of asparaginase as a chemotherapeutic agent.
Service Type: Chemotherapy drug administration.
Typical Site of Service: Infusion or injection setting, such as an outpatient facility or physician office.
Clinical & Coding Specifications
Clinical Context
A patient with acute lymphoblastic leukemia is scheduled for chemotherapy management that includes an intramuscular or intravenous injection of asparaginase. The service is delivered in an outpatient infusion center or office-based injection setting. The clinical workflow includes verification of the diagnosis and treatment plan, informed consent, drug preparation by pharmacy, administration by an oncology nurse, post-injection monitoring for hypersensitivity or pancreatitis, documentation of lot number and units administered, and billing using HCPCS Level II code J9020 for asparaginase in 10,000-unit increments.
Coding Specifications
-
Modifiers:
-
JW— Drug amount discarded/not administered to any patient: used when a portion of the dispensed asparaginase dose is discarded and the discarded amount must be reported separately from the amount administered. -
59— Distinct Procedural Service: used when the injection of asparaginase is a separate and distinct service from other procedures or services performed on the same day (e.g., separate encounter distinct from an infusion visit), and documentation supports a separate procedural service. -
Provider taxonomies and specialties:
-
207RH0003X— Hematology & Oncology Physician -
— Medical Oncology Physician